A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Virology Bookmark and Share

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Don J. Diamond, Ph.D. – Vaccine Research
Don Diamond, Ph.D., associate chair and the Tim Nesvig Lymphoma Research Fellow at City of Hope, directs the Division of Translational Vaccine Research (TVR), which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) and human immunodeficiency virus, or HIV. The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients. A therapeutic CMV peptide vaccine developed in the TVR is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, will initiate phase I human safety testing in fall 2013. A vaccine developed in the TVR also based on the MVA platform expressing unmutated p53 is undergoing phase I human testing in City of Hope gastrointestinal cancer patients. In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers. In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Translational Vaccine Research
The LVR was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology Faculty

Virology

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Don J. Diamond, Ph.D. – Vaccine Research
Don Diamond, Ph.D., associate chair and the Tim Nesvig Lymphoma Research Fellow at City of Hope, directs the Division of Translational Vaccine Research (TVR), which develops vaccines to combat hematologic malignancies, solid tumors, and infectious pathogens such as the herpesvirus, cytomegalovirus (CMV) and human immunodeficiency virus, or HIV. The prospect of an effective CMV vaccine means significant benefits for immunocompromised patients such as those with AIDS, or stem cell and solid organ transplant recipients. A therapeutic CMV peptide vaccine developed in the TVR is undergoing phase II human efficacy testing in City of Hope stem cell transplant recipients, while a second generation CMV vaccine based on the attenuated poxvirus MVA, or modified vaccinia Ankara, will initiate phase I human safety testing in fall 2013. A vaccine developed in the TVR also based on the MVA platform expressing unmutated p53 is undergoing phase I human testing in City of Hope gastrointestinal cancer patients. In the laboratory, we are refining a therapeutic platform based on attenuated Salmonella bacterium to treat a range of malignancies including pancreatic, skin and brain cancers. In collaboration with Peter Barry, Ph.D., of University of California at Davis and the National Primate Research Center, we are developing a prophylactic CMV vaccine that promises to control gestational infection that causes a wide range of birth defects that annually afflict close to 4,000 American children.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Translational Vaccine Research
The LVR was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology Faculty

Virology Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
NEWS & UPDATES
  • City of Hope is extending the reach of its lifesaving mission well beyond U.S. borders. To that end, three distinguished City of Hope leaders visited China earlier this year to lay the foundation for the institution’s new International Medicine Program. The program is part of City of Hope’s strategi...
  • A hallmark of cancer is that it doesn’t always limit itself to a primary location. It spreads. Breast cancer and lung cancer in particular are prone to spread, or metastasize, to the brain. Often the brain metastasis isn’t discovered until years after the initial diagnosis, just when patients were beginning to ...
  • Blueberries, cinnamon, baikal scullcap, grape seed extract (and grape skin extract), mushrooms, barberry, pomegranates … all contain compounds with the potential to treat, or prevent, cancer. Scientists at City of Hope have found tantalizing evidence of this potential and are determined to explore it to t...
  • Most women who are treated for breast cancer with a mastectomy do not choose to undergo reconstructive surgery. The reasons for this, according to a recent JAMA Surgery study, vary. Nearly half say they do not want any additional surgery, while nearly 34 percent say breast cancer reconstruction simply isn’t imp...
  • The leading risk factor for breast cancer is simply being a woman. The second top risk factor is getting older. Obviously, these two factors cannot be controlled, which is why all women should be aware of their risk and how to minimize those risks. Many risk factors can be mitigated, and simple changes can lead...
  • All women are at some risk of developing the disease in their lifetimes, but breast cancer, like other cancers, has a disproportionate effect on minorities. Although white women have the highest incidence of breast cancer, African-American women have the highest breast cancer death rates of all racial and ethni...
  • First, the good news: HIV infections have dropped dramatically over the past 30 years. Doctors, researchers and health officials have made great strides in preventing and treating the disease, turning what was once a death sentence into, for some, a chronic condition. Now, the reality check: HIV is still a worl...
  • Screening for breast cancer has dramatically increased the number of cancers found before they cause symptoms – catching the disease when it is most treatable and curable. Mammograms, however, are not infallible. It’s important to conduct self-exams, and know the signs and symptoms that should be checked by a h...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free.   In his previ...
  • In a single day, former professional triathlete Lisa Birk learned she couldn’t have children and that she had breast cancer. “Where do you go from there?” she asks. For Birk, who swims three miles, runs 10 miles and cycles every day, the answer  ultimately was a decision to take control of her cancer care. Afte...
  • More and more people are surviving cancer, thanks to advanced cancer treatments and screening tools. Today there are nearly 14.5 million cancer survivors in the United States. But in up to 20 percent of cancer patients, the disease ultimately spreads to their brain. Each year, nearly 170,000 new cases of brain ...
  • Cancer cells are masters of survival. Despite excessive damage to their most basic workings and the constant vigilance of the body’s immune system, they manage to persevere. Much of this extraordinary ability to survive falls under the control of proteins bearing the name STAT, short for signal transducer and a...
  • One person receives the breast cancer diagnosis, but the cancer affects the entire family. Couples, in particular, can find the diagnosis and treatment challenging, especially if they have traditional male/female communication styles. “Though every individual is unique, men and women often respond differently d...
  • Here’s a statistic you’ll hear and read frequently over the next month: One in eight women born in the United States will develop breast cancer at some point in her lifetime. Although this statement is accurate, based on breast cancer incidence rates in 2013, it’s often misunderstood. Leslie Bernstein, Ph.D., d...
  • This time of year, how can anyone not think pink? Through the power of pastel packaging, October has been etched permanently into the American public’s consciousness as Breast Cancer Awareness Month. The color pink is now synonymous with breast cancer. Suffice to say, awareness has been raised. Now itR...